This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
IL12 is a very potent cancer immunotherapy agent, but is difficult to harness safely if given systemically. Local gene transfer aims to confine the effects of IL12 to malignant tissues, thus avoiding toxicity. Lipid-nanoparticle mRNA achieves IL12 expression and efficacy in mouse models, opening the way to an ongoing trial.
See related article by Hewitt et al., p. 6284
Footnotes
Clin Cancer Res 2020;26:6080–2
- Received September 8, 2020.
- Revision received September 15, 2020.
- Accepted September 28, 2020.
- Published first October 1, 2020.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
December 2020
Volume 26, Issue 23
Volume 26, Issue 23
Interleukin-12 Message in a Bottle
Jump to section
Advertisement